ESC 2025: Semaglutide outperforms comparator in reducing cardiovascular events

At the recent European Society of Cardiology (ESC) Congress 2025, researchers presented new real-world data comparing semaglutide to tirzepatide. The data demonstrated that semaglutide was more effective than tirzepatide in reducing cardiovascular (CV) events in adults with obesity and established atherosclerotic cardiovascular disease (ASCVD) but without diabetes. The analysis, called STEER, provides the first direct comparative evidence of CV outcomes between the two obesity treatment drugs.